Safety and outcomes of dapagliflozin initiation in critically ill patients with acute kidney injury: A post-hoc analysis of the defender trial
Authors' conclusion
Dapagliflozin initiation in critically ill patients with AKI was not associated with excess mortality, KRT, or physiological derangement.
Study context
- Population
- Critically ill patients with acute kidney injury (AKI) at enrollment in the DEFENDER trial
- Participants
- 212 patients
- Comparison
- Dapagliflozin vs control
- Dapagliflozinn = 100
- Controln = 112reference
- Primary endpoint
- Mortality, kidney replacement therapy (KRT) and composite death/KRT
- Follow-up
- 28 days
Methodological detailsmixed models, likelihood ratios
- Mixed models
- Likelihood ratios
Primary result
As reported in the abstract
28-day mortality
Further findings
KRT · 28 days
Composite death/KRT · 28 days
Physiological trajectories (creatinine, urine output, fluid balance, acid-base), days 1-5
- No divergence suggestive of hemodynamic or metabolic instability
Likelihood ratios at 5% absolute effect threshold
- LR against harm
- 1.47
- LR against benefit
- 1.19
- Limited separation
Safety
Physiological trajectories (creatinine, urine output, fluid balance, acid-base), days 1-5
- No divergence suggestive of hemodynamic or metabolic instability
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Safety and outcomes of dapagliflozin initiation in critically ill patients with acute kidney injury: A post-hoc analysis of the defender trial. J Crit Care. Published 31 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →